Fig. 2: Overall survival (OS) among 18 patients with pancreatic cancer who received matched therapy.
From: Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
a OS in 18 patients. b OS in 5 patients who received targeted therapy as first line versus 13 patients who received it as ≥2nd line. c OS in 11 patients with matching score ≥50% versus 7 patients with matching score <50%. CI confidence interval, OS overall survival.
